Market watch: Innovation in the preclinical antibiotic pipeline

Nature Reviews Drug Discovery 16, 744 (2017).
doi:10.1038/nrd.2017.195

Authors: Ursula Theuretzbacher, Miloje Savic, Christine Årdal & Kevin Outterson
Antibiotic resistance is high on the political agenda and improving the antibiotic R&D pipeline is one of the major action points. The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) supports antibacterial projects through early preclinical development, with a 5-year budget totalling US$455 million (Nat.

Source: Nature Reviews Drug Discovery - October 6, 2017 Category: Drugs & Pharmacology Authors: Ursula Theuretzbacher Miloje Savic Christine Å rdal Kevin Outterson Tags: News and Analysis Source Type: research